Thursday Apr 10
A ray of hope for ficlatuzumab
AVEO Pharmaceuticals and Biodesix cross license their IP regarding AVEO's hepatocyte growth factor inhibitory antibody and Biodesix's companion diagnostic test for non-small cell lung cancer VeriStrat.
Fate Therapeutics Inc Files (8-K) Disclosing Change in Directors or...
Dr. Epstein is an epidemiologist and strategic consultant to life sciences companies and serves as a director on the boards of AVEO Pharmaceuticals, Inc., Illumina, Inc., a life sciences company, and , a managed healthcare company.
AVEO Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript
Thank you for holding for the AVEO conference call to discuss 2013 financial results and an update on 2014 strategy.
AVEO Announces Timing for Conference Call to Discuss Year-End 2013...
AVEO Oncology today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014.